STING Platform

About Liver Cancer

  • The incidence of liver cancer has more than tripled since 1980.
  • Hepatocellular carcinoma (HCC) is the most common form of liver cancer. In the United States, approximately 90% of primary liver cancers are HCCs.
  • HCC is the third most common and fastest growing cause of death from cancer worldwide, with a 5-year survival rate of 10%.
  • The current best treatment option for patients with HCC is transplantation, however only a small portion of patients qualify for a transplant due to strict criteria.

About Next Generation STING Agonists

All of Spring Bank’s next generation STING agonists are specifically designed to be conjugated with antibodies as antibody-drug conjugates (ADCs) for a possible targeted delivery approach. These compounds are more potent than currently available STING modulators and have the potential to be administered intravenously.

About SB 11285

STimulator of INterferon Genes, or STING, is a protein that has the power to activate the body’s innate immune system. Targeting this protein gives us the potential to stimulate the body’s immune response in the presence of diseases such as cancer.


SB 11285 is a potent immunotherapeutic agent that activates the STING pathway. It is currently being developed for the treatment of selected cancers, including liver cancer. Due to its chemistry, SB 11285 has the potential to be conjugated to antibodies for a targeted delivery approach. SB 11285 can be administered intravenously.

Clinical Trials

We plan to submit an IND and/or a CTA for SB 11285 in mid-2018, and, if cleared, commence Phase 1b/2 clinical trials in liver cancer in the second half of 2018.